相关实验视频
Updated: May 22, 2025

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
16.8K
AgeNet-SHAP:一种可解释的AI方法,以优化绘制多变量区域大脑年龄和阿尔茨海默病临床严重性模式
Gauri Darekar1,2, Taslim Murad1, Hui-Yuan Miao1
1Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
medRxiv : the preprint server for health sciences
|March 17, 2025
概括
人工智能准确地预测大脑年龄,识别关键的大脑区域. 这种方法有助于理解衰老和诊断神经退行性疾病,如阿尔茨海默病.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 老年学是一门学科.
背景情况:
- 年龄是轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 的主要危险因素.
- 了解大脑衰老模式对于正常衰老和MCI/AD进展至关重要.
- 与单变量关系相比,大脑区域和年龄之间的多变量关联尚未得到充分探索.
研究的目的:
- 采用人工智能 (AI) 用MRI数据来预测大脑年龄.
- 使用AI和SHAP识别与年龄相关的显著多变量大脑区域.
- 验证AI方法在预测大脑年龄及其与认知状态的关联方面.
主要方法:
- 利用668个MRI扫描数据集进行大脑年龄预测.
- 对比了各种AI模型,选择了深度学习模型 (AgeNet) 以获得卓越的性能.
- 集成的AgeNet与Shapley添加式解释 (SHAP) 进行特征重要性分析 (AgeNet-SHAP).
主要成果:
- 深度学习模型 (AgeNet) 在大脑年龄预测方面显著超过传统机器学习模型.
- 在模拟中,AgeNet-SHAP成功地确定了预测大脑年龄的关键大脑区域.
- 与认知正常 (CN) 个体相比,MCI和AD组显示出不同的大脑区域差异的独特模式,AD表现出更广泛的变化.
- 个性化的AgeNet-SHAP特征与AD连续体中的临床严重程度相关.
结论:
- 人工智能,特别是与SHAP集成的深度学习,为大脑年龄预测提供了强大的工具.
- AgeNet-SHAP方法有效地识别了与衰老和神经退行相关的关键大脑区域.
- 这种方法支持诊断,预后和针对认知衰退的个性化医学的进步.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.大脑 年龄 大脑年龄深度学习 (DL) 是指深度学习.特性重要性 特性重要性机器学习 (ML) 是指机器学习.轻度认知障碍 (MCI) 是一种轻度认知障碍.沙普利的添加式扩展 (SHAP)更多相关视频
14:27Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
15.6K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
39.7K
相关概念视频
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141